Primaquine-thiazolidinones block malaria transmission and development of the liver exoerythrocytic forms

Anna Caroline C Aguiar, Flávio Jr B Figueiredo, Patrícia D. Neuenfeldt, Tony H. Katsuragawa, Bruna B. Drawanz, Wilson Cunico, Photini Sinnis, Fidel P Zavala, Antoniana U. Krettli

Research output: Contribution to journalArticle

Abstract

Background: Primaquine is an anti-malarial used to prevent Plasmodium vivax relapses and malaria transmission. However, PQ metabolites cause haemolysis in patients deficient in the enzyme glucose-6-phosphate dehydrogenase (G6PD). Fifteen PQ-thiazolidinone derivatives, synthesized through one-post reactions from primaquine, arenealdehydes and mercaptoacetic acid, were evaluated in parallel in several biological assays, including ability to block malaria transmission to mosquitoes. Results: All primaquine derivatives (PQ-TZs) exhibited lower cell toxicity than primaquine; none caused haemolysis to normal or G6PD-deficient human erythrocytes in vitro. Sera from mice pretreated with the test compounds thus assumed to have drug metabolites, caused no in vitro haemolysis of human erythrocytes, whereas sera from mice pretreated with primaquine did cause haemolysis. The ability of the PQ-TZs to block malaria transmission was evaluated based on the oocyst production and percentage of mosquitoes infected after a blood meal in drug pre-treated animals with experimental malaria caused by either Plasmodium gallinaceum or Plasmodium berghei; four and five PQ-TZs significantly inhibited sporogony in avian and in rodent malaria, respectively. Selected PQ-TZs were tested for their inhibitory activity on P. berghei liver stage development, in mice and in vitro, one compound (4m) caused a 3-day delay in the malaria pre-patent period. Conclusions: The compound 4m was the most promising, blocking malaria transmissions and reducing the number of exoerythrocytic forms of P. berghei (EEFs) in hepatoma cells in vitro and in mice in vivo. The same compound also caused a 3-day delay in the malaria pre-patent period.

Original languageEnglish (US)
Article number110
JournalMalaria Journal
Volume16
Issue number1
DOIs
StatePublished - Mar 9 2017

Keywords

  • Blocking malaria transmission
  • Exoerythrocytic stages, sporozoites
  • Malaria
  • Plasmodium berghei
  • Plasmodium gallinaceum
  • Sporogony
  • Thiazolidinones

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Primaquine-thiazolidinones block malaria transmission and development of the liver exoerythrocytic forms'. Together they form a unique fingerprint.

  • Cite this

    Aguiar, A. C. C., Figueiredo, F. J. B., Neuenfeldt, P. D., Katsuragawa, T. H., Drawanz, B. B., Cunico, W., Sinnis, P., Zavala, F. P., & Krettli, A. U. (2017). Primaquine-thiazolidinones block malaria transmission and development of the liver exoerythrocytic forms. Malaria Journal, 16(1), [110]. https://doi.org/10.1186/s12936-017-1755-6